Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.
暂无分享,去创建一个
M. Kattan | S. Shariat | K. Slawin | E. Canto
[1] R. Kane,et al. Prostate‐specific antigen lewels in 1695 men without evidence of prostate cancer: Findings of the American cancer society national prostate cancer detection project , 2010, Cancer.
[2] T. Wheeler,et al. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. , 2004, The Journal of urology.
[3] T. Wheeler,et al. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. , 2004, Urology.
[4] M. Kattan,et al. Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression , 2004, Clinical Cancer Research.
[5] Michael W Kattan,et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Kattan,et al. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. , 2002, Cancer research.
[7] Pierre I Karakiewicz,et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Partin,et al. Free prostate-specific antigen in serum is becoming more complex. , 2002, Urology.
[9] M. Kattan,et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. , 2002, The Journal of urology.
[10] M. Kattan,et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Kattan,et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.
[12] M. Ittmann,et al. Interleukin-6 is an autocrine growth factor in human prostate cancer. , 2001, The American journal of pathology.
[13] A. Haese*,et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml , 2001, The Prostate.
[14] J. Blasko,et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.
[15] J. Hugosson,et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. , 2001, Clinical chemistry.
[16] C. Roehrborn,et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. , 2001, Urology.
[17] M. Kattan,et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Yousef,et al. The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.
[19] T. Tammela,et al. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. , 2000, The Journal of urology.
[20] S. Loening,et al. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. , 2000, Anticancer research.
[21] K. Slawin,et al. Seminal plasma contains “BPSA,” a molecular form of prostate‐specific antigen that is associated with benign prostatic hyperplasia , 2000, The Prostate.
[22] E. Metter,et al. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[23] T. Stamey,et al. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. , 2000, The Journal of urology.
[24] M W Kattan,et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Kattan,et al. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. , 2000, Urology.
[26] G. Wise,et al. Cytokine variations in patients with hormone treated prostate cancer. , 2000, Journal of Urology.
[27] T. Tammela,et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. , 2000, The Journal of clinical endocrinology and metabolism.
[28] T. Hill,et al. Different proportions of various prostate‐specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen‐induced LNCaP cells , 2000, The Prostate.
[29] Y. Horiguchi,et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] T. Wheeler,et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. , 2000, Cancer research.
[31] H. Lilja,et al. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. , 2000, Clinical chemistry.
[32] W. Catalona,et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.
[33] D. Tindall,et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. , 1999, Urology.
[34] J. Richie,et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.
[35] D. Chan,et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. , 1999, Urology.
[36] D. Tindall,et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. , 1999, Clinical chemistry.
[37] H. Miyake,et al. Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer , 1999, The Prostate.
[38] M. Kattan,et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] P. Boyle,et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. , 1999, Urology.
[40] J. Simons,et al. Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.
[41] H. Klocker,et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.
[42] M. Stampfer,et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.
[43] C. Mantzoros,et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.
[44] A W Partin,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[45] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[46] V. Speights,et al. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. , 1998, The Journal of urology.
[47] J. Hugosson,et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. , 1998, The Journal of urology.
[48] G G Klee,et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.
[49] D. Ornstein,et al. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.
[50] E. Metter,et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.
[51] F. Gauthier,et al. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. , 1996, Journal of andrology.
[52] W. Catalona,et al. Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.
[53] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[54] J. Thrasher,et al. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. , 1996, The Journal of urology.
[55] U. Stenman,et al. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. , 1995, Clinical chemistry.
[56] J. Simons,et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.
[57] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[58] T. Wheeler,et al. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. , 1994, The Journal of urology.
[59] M. Papa,et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.
[60] T. Stamey,et al. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.
[61] O. Nilsson,et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.
[62] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[63] B. Binder,et al. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. , 1988, The Journal of urology.
[64] T. Stamey,et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.
[65] S. Loening,et al. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. , 2002, Urology.
[66] A. Lu,et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.
[67] M. Kattan,et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] P. Schellhammer,et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. , 2000, The Journal of urology.
[69] S. Loening,et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. , 2000, Clinical chemistry.
[70] T. Stamey,et al. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. , 2000, The Journal of urology.
[71] R. Wolfert,et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. , 2000, Urology.
[72] M. Kattan,et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.
[73] W. Catalona,et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. , 1998, The Journal of urology.
[74] M. Saedi,et al. Human glandular kallikrein, hK2, shows arginine‐restricted specificity and forms complexes with plasma protease inhibitors , 1998, The Prostate.
[75] J. Thrasher,et al. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. , 1996, The Journal of clinical endocrinology and metabolism.
[76] A. Melman,et al. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. , 1995, Nature medicine.
[77] P. Scardino,et al. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. , 1993, Human pathology.
[78] M. Steiner,et al. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.
[79] U. Stenman,et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.
[80] R. Babaian,et al. Prostate‐specific antigen and prostate gland volume: Correlation and clinical application , 1990, Journal of clinical laboratory analysis.